IBD is an autoimmune condition (your immune system attacks your own body), that comes in two forms: Ulcerative Colitis (UC) and Crohn’s Disease (CD). These two conditions create dysfunction within the gastrointestinal tract and further impact the immune system.
Current medications for these conditions are not very effective and have significant side effects. The medication in this study is given as an oral tablet and has been found to reduce inflammation in the bowels. For the initial stage of research into this medication, we require healthy participants with no medical conditions. This is so we can look at how the body metabolises the medication. At a later stage, it is hoped the medication will go on to be tested in patients with IBD.
The trial has been approved by an independent ethics committee and participants will be reimbursed for their time.